Humana faces severe headwinds from rising medical costs and a dramatic drop in 4-STAR Medicare Advantage membership, pressuring margins and profitability. Learn more about HUM stock here.
On February 25, Barclays lowered its price recommendation on Humana Inc. (NYSE:HUM) to $176 from $245. The firm reiterated an Equal Weight rating on the shares.
See Humana Inc. (HUM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results